^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Licartin (Iodine-131-labeled metuximab)

    Associations

    News

    Trials
    Company:
    Chinese Government
    Drug class:
    Beta radiation emitter, CD147 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost5years
    Efficacy of licartin combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced primary liver cancer. (PubMed, J BUON)
    Licartin combined with TACE has better efficacy than TACE alone in the treatment of middle-advanced primary liver cancer, with tolerable adverse reactions, which prolongs patients' survival time.
    Clinical • Journal
    |
    AFP (Alpha-fetoprotein)
    |
    Licartin (Iodine-131-labeled metuximab)